Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AtaiBeckley Inc. - Common Stock (NQ:ATAI)

3.705 +0.055 (+1.51%)
Streaming Delayed Price Updated: 3:06 PM EDT, Mar 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,580,075
Open 3.695
Bid (Size) 3.700 (4,400)
Ask (Size) 3.710 (8,100)
Prev. Close 3.650
Today's Range 3.580 - 3.728
52wk Range 1.150 - 6.750
Shares Outstanding 166,010,476
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day
From AtaiBeckley Inc.
Via GlobeNewswire

Performance

YTD
-4.3%
-4.3%
1 Month
-2.5%
-2.5%
3 Month
-10.5%
-10.5%
6 Month
-20.3%
-20.3%
1 Year
+153.8%
+153.8%

More News

Read More
News headline image
ENDRA Life Sciences (NASDAQ: NDRA): The GLP-1 Healthcare Boom Offering Tremendous Opportunity Watch HIMS, ANTX, ATAI, PURR Now!
Via AB Newswire
News headline image
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley To Host Virtual Investor Day on March 6, 2026
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Appoints Michael Faerm as Chief Financial Officer
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley To Participate in Upcoming Investor Conferences
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 ↗
Via MarketBeat
News headline image
AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment ↗
Via Stocktwits
News headline image
AtaiBeckley Completes Redomiciliation to the United States
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
MarketBeat’s Top 5 Rated Small-Cap Stocks ↗
Via MarketBeat
News headline image
Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order ↗
Via Stocktwits
Topics Cannabis ETFs Government
News headline image
AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
Analyst Expectations For ATAI Life Sciences's Future ↗
Via Benzinga
News headline image
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
From atai Life Sciences
Via GlobeNewswire
News headline image
Why Atai Life Sciences Stock Was So Lively This Week ↗
Via The Motley Fool

Frequently Asked Questions

Is AtaiBeckley Inc. - Common Stock publicly traded?
Yes, AtaiBeckley Inc. - Common Stock is publicly traded.
What exchange does AtaiBeckley Inc. - Common Stock trade on?
AtaiBeckley Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for AtaiBeckley Inc. - Common Stock?
The ticker symbol for AtaiBeckley Inc. - Common Stock is ATAI on the Nasdaq Stock Market
What is the current price of AtaiBeckley Inc. - Common Stock?
The current price of AtaiBeckley Inc. - Common Stock is 3.705
When was AtaiBeckley Inc. - Common Stock last traded?
The last trade of AtaiBeckley Inc. - Common Stock was at 03/17/26 03:06 PM ET
What is the market capitalization of AtaiBeckley Inc. - Common Stock?
The market capitalization of AtaiBeckley Inc. - Common Stock is 615.07M
How many shares of AtaiBeckley Inc. - Common Stock are outstanding?
AtaiBeckley Inc. - Common Stock has 615M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.